Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Up – Should You Buy?

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s share price gapped up prior to trading on Friday . The stock had previously closed at $24.12, but opened at $25.81. Lyell Immunopharma shares last traded at $25.5950, with a volume of 3,805 shares traded.

Analysts Set New Price Targets

A number of equities analysts recently commented on LYEL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and increased their target price for the company from $20.00 to $45.00 in a report on Tuesday, December 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $45.00.

Lyell Immunopharma Stock Down 0.1%

The stock has a market cap of $548.52 million, a price-to-earnings ratio of -1.12 and a beta of -0.13. The business has a 50-day moving average of $26.98 and a 200-day moving average of $18.14.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. Equities analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of Lyell Immunopharma

Several large investors have recently added to or reduced their stakes in LYEL. Millennium Management LLC increased its stake in shares of Lyell Immunopharma by 140.0% during the 3rd quarter. Millennium Management LLC now owns 125,361 shares of the company’s stock worth $2,036,000 after purchasing an additional 73,132 shares during the last quarter. Foresite Capital Management V LLC increased its position in Lyell Immunopharma by 17.3% during the third quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock worth $7,748,000 after buying an additional 70,426 shares during the last quarter. ARCH Venture Management LLC raised its holdings in Lyell Immunopharma by 51.5% during the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after buying an additional 938,438 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Lyell Immunopharma by 107.0% in the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after acquiring an additional 10,768 shares in the last quarter. Finally, Takeda Pharmaceutical Co. Ltd. raised its position in shares of Lyell Immunopharma by 33.3% in the third quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company’s stock valued at $891,000 after purchasing an additional 13,722 shares during the period. 66.05% of the stock is owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.